ストックスクリーナーアプリを入手
1.56
9.09%
0.13
プレマーケット:
1.56
前日終値:
$1.43
開ける：
$1.46
24時間の取引高:
2.11M
Relative Volume:
0.66
時価総額：
$440.85M
収益：
$53.43M
当期純損益:
$-52.49M
株価収益率:
-4.3466
EPS:
-0.3589
ネットキャッシュフロー:
$-58.29M
1週間 パフォーマンス:
+3.31%
1か月 パフォーマンス:
-8.77%
6か月 パフォーマンス:
+36.84%
1年 パフォーマンス:
+136.47%
1日の値動き範囲:
$1.45
$1.59
1週間の範囲:
$1.37
$1.59
52週間の値動き範囲:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Compare IVVD vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.56 | 440.85M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-22 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Invivyd Inc (IVVD) 最新ニュース
Analysis Recap: What is the target price for Invivyd Inc stockTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Insider Buy: How liquid is Invivyd Inc stock2026 Breakouts & Breakdowns & Weekly Top Performers Watchlists - baoquankhu1.vn
Aug Gainers: What is the target price for Invivyd Inc stock2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching (NASDAQ:IVVD) - Seeking Alpha
Inflation Data: Is Invivyd Inc exposed to currency risksWeekly Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
Invivyd Earnings Call Highlights Pivotal Trial Momentum - The Globe and Mail
Invivyd (NASDAQ:IVVD) Stock Price Up 6.3%Still a Buy? - MarketBeat
Invivyd appoints Michael Mina as chief medical officer - Investing.com Nigeria
Invivyd, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IVVD) 2026-03-08 - Seeking Alpha
Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Analysts - MarketBeat
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com Canada
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Invivyd Q4 Earnings Call Highlights - MarketBeat
Michael Mina Appointed Chief Medical Officer at Invivyd - geneonline.com
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com Australia
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com Nigeria
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Globe and Mail
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Invivyd FY revenue rises; operating expenses cut sharply - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
COVID testing voice Michael Mina now steering antibody drug effort - Stock Titan
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
New study maps COVID protection to antibody levels, not variants - Stock Titan
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - The Globe and Mail
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com UK
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):